| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C50H47Cl2N3O6 |
| SMILES | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
TT-OAD2 free base is a non-peptide agonist of the glucagon-like peptide-1 (GLP-1) receptor, with an EC50 of 5 nM, and has potential for use in the treatment of diabetes[1][2]. It has the molecular formula C50H47Cl2N3O6 and a molecular weight of 856.83 g/mol.
Physical & Chemical Properties
| CAS Number | 1246826-07-2 |
|---|---|
| Molecular Formula | C50H47Cl2N3O6 |
| Molecular Weight | 856.83 g/mol |
| SMILES | O=C(O)[C@H](CC1=CC=C(C2=C(C)C(C)=NC=C2)C=C1)NC([C@H]3N([C@H](C4=CC=CC=C4)CC)CC5=C(C=C(OC[C@H](C6=CC=C(OCC7=CC=C(Cl)C(Cl)=C7)C=C6)O8)C8=C5)C3)=O |
| Signaling Pathway | GPCR/G Protein |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
Activity & Target
EC50: 5 nM (GLP-1 receptor)[2]
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
[2]. Transtech Pharma, et al. Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof. WO2010114824A1.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with your institution's chemical hygiene plan.
In Vitro
In HEK293A cells, TT-OAD2 (0-10 μM) suppresses the cAMP, calcium, pERK1/2 and β-arrestin responses mediated by GLP-1 and oxyntomodulin, in a concentration-dependent manner[1].
In Vivo
In male human GLP-1 receptor knock-in and knockout mice, intravenous TT-OAD2 (3 mg/kg) induces plasma insulin during an acute IVGTT, in humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice[1].
| Animal Model | Male human GLP-1 receptor knock-in and knockout mice (6-11 months of age) with intravenous glucose tolerance tests[1] |
|---|---|
| Dosage | 3 mg/kg |
| Administration | Intravenous injection (Single dose) |
| Result | Induced plasma insulin. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
